10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.875.1999



Fads3 Antibody - N-terminal region

Rabbit Polyclonal Antibody Catalog # AI13061

Product Information

Application WB
Primary Accession Q8K1P9

Other Accession <u>NM 173137, NP 775160</u>

ReactivityHuman, Mouse, Rat, Rabbit, Pig, Dog, Guinea Pig, Horse, Bovine **Predicted**Human, Mouse, Rat, Rabbit, Pig, Dog, Guinea Pig, Horse, Bovine

Host Rabbit
Clonality Polyclonal
Calculated MW 51467

Additional Information

Gene ID 286922

Other Names Fatty acid desaturase 3, 1.14.19.-, Fads3

Format Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium

azide and 2% sucrose.

Reconstitution & Storage Add 50 ul of distilled water. Final anti-Fads3 antibody concentration is 1

mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at

20°C. Avoid repeat freeze-thaw cycles.

Precautions Fads3 Antibody - N-terminal region is for research use only and not for use in

diagnostic or therapeutic procedures.

Protein Information

Name Fads3 {ECO:0000303 | PubMed:19752397, ECO:0000303 | PubMed:24070791}

Function Mammals have different sphingoid bases that differ in their length and/or

pattern of desaturation and hydroxyl groups. The predominant sphingoid base that comprises mammalian ceramides is sphing-4-enine (sphingosine or SPH) which has a trans (E) desaturation at carbon 4. FADS3 is a desaturase that introduces a cis (Z) double bond between carbon 14 and carbon 15 of the sphingoid base (also known as long chain base, LCB), producing LCBs such as sphinga-4,14-dienine (SPD, d18:2(4E,14Z)) from SPH. Prefers SPH-containing ceramides (N- acylsphing-4-enines) as substrates. Capable of metabolizing also the SPH in its free form. SPD ceramides occur widely in mammalian tissues and cells. Due to their unusual structure containing a cis double bond, SPD ceramides may have an opposite, negative role in lipid microdomain formation relative to conventional ceramides. Could be involved in the

detoxification of 1-deoxy sphingolipids, by desaturating the cytotoxic 1-deoxysphinganine (1-deoxySA, m18:0), produced under pathological conditions, to 1-deoxysphingenine (1-deoxysphingosine, 1-deoxySO, m18:1). Although prefers SPH-containing ceramides (N-acylsphing-4- enines) as substrates, it also exhibits activity toward dihydrosphingosine-containing CERs (N-acylsphinganines) and produces 14Z-SPH-containing sphingolipids. Its desaturase mechanism involves an electron transfer facilitated by cytochrome b5 (By similarity). FADS3 also acts as a methyl-end fatty acyl coenzyme A (CoA) desaturase that introduces a cis double bond between the preexisting double bond and the terminal methyl group of the fatty acyl chain. Desaturates (11E)-octadecenoate (trans-vaccenoate, the predominant trans fatty acid in human milk) at carbon 13 to generate (11E,13Z)-octadecadienoate (also known as conjugated linoleic acid 11E,13Z-CLA) (PubMed:24070791,

PubMed:30262139).

Cellular Location Endoplasmic reticulum membrane {ECO:0000250 | UniProtKB:Q9Y5Q0};

Multi-pass membrane protein

Tissue Location Essentially expressed in liver and kidney and to a lesser extent in heart,

adipose tissue, stomach and pancreas (at protein level) (PubMed:19752397).


Higher expression in lactating mammary gland than in liver

(PubMed:30262139)

References

D'Andrea S., et al. Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.

Images



Host: Rabbit Target Name: Fads3

Sample Tissue: Rat Kidney lysates Antibody Dilution: 1.0µg/ml

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.